Cardiola Penetrates European Market with Its Muscular CounterPulsation (MCP)-based m.pulse(R) system

WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today that it has placed its patented m.pulse® system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse® is the world’s first and only device enabling CAD patients to receive MCP therapy at home.